Navigation Links
The MedZilla Report: May 2009 Employment Outlook for Biotech/Pharma/Health
Date:6/24/2009

Health care employment rebounded in May, with 24,000 new jobs created even amid widespread announcements of layoffs. Pharmaceutical companies, though, laid off fewer employees in May than in any previous month of 2009.

Seattle, WA (Vocus) June 24, 2009 -- Health care employment saw May as something of a rebound month, with 24,000 new jobs created in the industry -- 7,000 more than in April. Average monthly job growth has remained steady in 2009. However, heavy layoffs also struck health care, with several companies announcing as many as 500 positions eliminated. Pharmaceuticals, conversely, announced relatively few layoffs compared to the previous six months.

   

By far the largest layoff in May was announced by Medtronic, who, according to the Associated Press, faced a 69 percent drop in profits after fourth quarter 2008. Minnesota-based health systems continued feeling the pinch, as did several facilities across New England. New Jersey's Horizon Blue Cross Blue Shield said a combination of factors including employers cutting the benefits they offer employees, which in turn affects the amount of money coming in to the insurer (The Star-Ledger, May 5, 2009). Most job elimination announcements came as a result of the downward trend in the United States economy, which has yet to turn around.
   
Despite layoffs, employers continued posting jobs on employment websites. New Jersey and Massachusetts both had substantial increases in the number of jobs posted -- 2.5 and 3.5 percent, respectively -- and no state saw a drop of more than one percent. The real change in postings came as a result of what types of jobs were posted; business development jobs, including research, were posted about 10 percent more overall than in April, while sales, marketing, and management positions all declined by an average of four percent. Meanwhile, employers actively sea
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health
2. The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
3. The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health
4. The MedZilla Report: March 2009 Employment Outlook for Biotech/Pharma/Health
5. The MedZilla Report: April 2009 Employment Outlook for Biotech/Pharma/Health
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
9. Rabobank Releases Annual North American Food & Agribusiness Outlook
10. ViroPharma Provides 2008 Outlook
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The MedZilla Report: May 2009 Employment Outlook for Biotech/Pharma/Health
(Date:6/1/2015)... Research and Markets ( http://www.researchandmarkets.com/research/lkcspr/2015_strategies ... "2015 Strategies in European Immunoprotein Diagnostic ... This new 273-page report provides ... including emerging tests, technologies, instrumentation, sales forecasts, ... suppliers. Companies Mentioned: - ...
(Date:6/1/2015)... June 1, 2015  OncoSec Medical Inc. ("OncoSec") ... intratumoral cancer immunotherapies, today announced a collaboration with ... Veterinary Medicine to test ImmunoPulse™ IL-12 as an ... primary goals of the canine study are to ... of ImmunoPulse™ IL-12 and validate key clinical biomarkers. ...
(Date:6/1/2015)... Hutchison China MediTech Limited ... (publ) ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, ... clinical trial of HMP,s c-Met inhibitor savolitinib (AZD6094) ... cell lung cancer ("NSCLC"). AZD9291 is ... receptor (EGFR). Preliminary data on the activity of ...
(Date:5/31/2015)... 31, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... oncology and drug-delivery therapies, today announced interim findings ... its investigational new drug PEGPH20 for the potential ... The encouraging interim data was presented today ... meeting in an oral presentation by Principal Investigator ...
Breaking Biology Technology:OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 2OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 3OncoSec Medical and UC Davis School of Veterinary Medicine Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma 4Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5
... Aug. 2, 2011 Cephalon, Inc. (Nasdaq: CEPH ... million, a 2 percent increase compared to net sales of ... per common share for the period was $1.54 compared to ... and certain other items, adjusted net income for the second ...
... 2011 Enzymatics, Inc., ( www.enzymatics.com ) a leading ... Boston Chamber of Commerce with a "Top 10 Small ... Honorees include dynamic small and high growth businesses in ... excellence, product innovation, and social responsibility.  An awards luncheon ...
... N.Y. Every year, millions of people contend with ... their pain, Cornell University engineers in Ithaca and doctors ... City have created a biologically based spinal implant that ... Lawrence Bonassar, Ph.D., associate professor of biomedical engineering ...
Cached Biology Technology:Cephalon Reported Financial Results for the Second Quarter of 2011 2Cephalon Reported Financial Results for the Second Quarter of 2011 3Cephalon Reported Financial Results for the Second Quarter of 2011 4Cephalon Reported Financial Results for the Second Quarter of 2011 5Cephalon Reported Financial Results for the Second Quarter of 2011 6Cephalon Reported Financial Results for the Second Quarter of 2011 7Cephalon Reported Financial Results for the Second Quarter of 2011 8Cephalon Reported Financial Results for the Second Quarter of 2011 9Cephalon Reported Financial Results for the Second Quarter of 2011 10Cephalon Reported Financial Results for the Second Quarter of 2011 11Cephalon Reported Financial Results for the Second Quarter of 2011 12Enzymatics Honored With a Top 10 Small Business of the Year Award 2In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 2In the battle to relieve back aches, Cornell researchers create bioengineered spinal disc implants 3
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) ... Recognition Market by Solution, by Software, by Hardware, ... report to their offering. The ... become more efficient and cost effective. This has ... from the commercial sector. The development of 3D ...
(Date:5/22/2015)... 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... be ending its promotional pricing and making the Wocket generally ... Laurence Savin , Head of Marketing said, "We,ve extended the ... the end of May. To get your wocket at this ... open the store on June 1, you,ll receive a unique ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... recently discovered that a chemical chain reaction that controls ... could mean the difference between normal growth and cancer. ... Cell, describes how organs can grow uncontrollably huge and ... This chain reaction, a domino-like chain of events ...
... HONOLULU, Sept. 20 Women with low levels of vitamin ... a study led by the University of Pittsburgh Graduate School ... meeting of the American Society for Bone and Mineral Research ... professor of epidemiology, and colleagues evaluated patient data on 400 ...
... Nile virus first struck New York City in 1999, ... public health officials alike, showing that even affluent, urban ... virus has been widely studied, there is still little ... between urban and rural areas. Assistant professor at ...
Cached Biology News:Controlling for size may also prevent cancer 2Low vitamin D linked to higher risk of hip fracture 2UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC 2
Nestin, Human...
Ezrin/Radixin/Moesin Antibody...
... Taura Syndrome Virus Coat Protein ... tested applications). ... MNDIPITNQN VVLSKNVTDN LFEVQDQALI ESLSRDVLLH NDSWTSSDDE ... terminal amino acids 25/100 of ...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Biology Products: